The Effect of Selective Retina Therapy for Bevacizumab-Resistant Chronic Central Serous Chorioretinopathy
Ophthalmologica · 2022 · 245 (1) · 91-100
DOI: 10.1159/000520187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmologica, online erschienen am 14.10.2021. Verfasst von Seung Hee Jeon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Central Serous Chorioretinopathy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
The aim of this study was to evaluate the efficacy of selective retina therapy (SRT), used in conjunction with real-time feedback dosimetry (RFD), in the treatment of bevacizumab-resistant chronic central serous chorioretinopathy (CSC). Patients and Methods: In this retrospective cohort study, 22 eyes of 22 patients with bevacizumab-resistant chronic CSC, showing focal or diffuse foveal leakages on fundus fluorescein angiography (FFA), were included. After evaluation of the test spots at temporal arcades, SRT (wavelength, 527 nm; pulse repetition rate, 100 Hz; ramping over maximal 15 micropulses; and spot diameter, 200 μm) using RFD was applied to the leakage sites observed on FFA. Changes in the mean best-corrected visual acuity (BCVA), central macular thickness (CMT), and subretinal fluid (SRF) height were evaluated at baseline and at 1, 3, 6, 9, and 12 months following treatment.
Results
SRF completely resolved in 81.8% (18/22 eyes) cases at 12 months post-treatment. The mean BCVA (logarithm of the minimum angle of resolution [logMAR]) improved from 0.49 ± 0.29 at baseline to 0.43 ± 0.36 at 12 months (p = 0.067). The mean BCVA gain was 0.06 logMAR, equivalent to 3 ETDRS letters. The CMT significantly decreased from 323 ± 85.6 μm at baseline to 221.5 ± 60.4 μm at 12 months (p < 0.001). The mean SRF height also significantly decreased from 174.6 ± 86.4 μm at baseline to 35.1 ± 75.4 μm at 12 months (p < 0.001).
Conclusion
SRT showed favorable visual and anatomical outcomes in patients with bevacizumab-resistant chronic CSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Science, Catholic University of Korea, Seoul, Republic of Korea.
Zitieren
APA
Jeon, S. H., Kim, M., Lee, J., & Roh, Y. J. (2022). The Effect of Selective Retina Therapy for Bevacizumab-Resistant Chronic Central Serous Chorioretinopathy. Ophthalmologica, 245(1), 91-100. https://doi.org/10.1159/000520187
Vancouver
Jeon SH, Kim M, Lee J, Roh YJ. The Effect of Selective Retina Therapy for Bevacizumab-Resistant Chronic Central Serous Chorioretinopathy. Ophthalmologica. 2022;245(1):91-100. doi:10.1159/000520187
BibTeX
@article{Jeon2022,
author = {Jeon, Seung Hee and Kim, Minhee and Lee, Jiyoung and Roh, Young-Jung},
title = {The Effect of Selective Retina Therapy for Bevacizumab-Resistant Chronic Central Serous Chorioretinopathy},
journal = {Ophthalmologica},
year = {2022},
volume = {245},
number = {1},
pages = {91--100},
doi = {10.1159/000520187}
}
EUVIMED